“An early-retiring nurse told me the lockdown protocols have turned our healthcare facilities into ‘death processing centers’. I'm starting to grasp what she meant.”
If you want to grasp why nursing burnout in long-term care is a thing, maybe look a little deeper at what’s really going on, but staff are not comfortable saying out loud
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
“The potential to deliver ‘one-shot cures’ is one of the most attractive aspects of gene therapy... However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
-- Salveen Richter, Financial Analyst, Goldman Sachs, April 2018
Hope you don't mind if I share some links. Apologies if your readers have already seen them.
Dr. Igor Shepherd, Wyoming Physician
https://www.lewrockwell.com/2022/05/dr-igor-shepherd/the-body-snatchers-the-nwos-eugenics-agenda/
During the pandemic, Canadian long term care facility denied patients access to vitamins & supplements.
https://lionessofjudah.substack.com/p/ontario-ltc-residents-were-denied
Fact Check: Midazolam Stockpile
https://fullfact.org/online/david-icke-midazolam/
2018: Curing Disease Is Bad For Business
https://www.truthdig.com/articles/wall-street-admits-curing-diseases-is-bad-for-business/
https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
“The potential to deliver ‘one-shot cures’ is one of the most attractive aspects of gene therapy... However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
-- Salveen Richter, Financial Analyst, Goldman Sachs, April 2018